Can-Fite BioPharma Ltd. announced on September 2, 2026, that blinded overall survival data from its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma appears longer than originally anticipated based on initial study design assumptions. The company is evaluating an earlier timing for the planned interim analysis to enable an independent assessment of overall survival between treatment groups. These observations reflect the pooled, blinded population including placebo recipients, so no conclusions regarding treatment efficacy can be drawn at this stage. Can-Fite BioPharma Ltd. operates in the biotechnology industry, developing proprietary small molecule drugs targeting oncological and inflammatory diseases.
